G

GI Innovation Inc
KOSDAQ:358570

Watchlist Manager
GI Innovation Inc
KOSDAQ:358570
Watchlist
Price: 13 330 KRW -7.94% Market Closed
Market Cap: 848.7B KRW

Net Margin

-15 377%
Current
Improving
by 14 036.4%
vs 3-y average of -29 413.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-15 377%
=
Net Income
₩-52B
/
Revenue
₩338.1m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-15 377%
=
Net Income
₩-52B
/
Revenue
₩338.1m

Peer Comparison

Country Company Market Cap Net
Margin
KR
GI Innovation Inc
KOSDAQ:358570
921.9B KRW
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
178.1B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
154.2B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.2B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.9B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.9B USD
Loading...
No Stocks Found

Market Distribution

Lower than 99% of companies in Korea
Percentile
1st
Based on 2 632 companies
1st percentile
-15 377%
Low
-168 471.3% — -2.9%
Typical Range
-2.9% — 5.8%
High
5.8% — 21 012.5%
Distribution Statistics
Korea
Min -168 471.3%
30th Percentile -2.9%
Median 1.9%
70th Percentile 5.8%
Max 21 012.5%

GI Innovation Inc
Glance View

Market Cap
848.7B KRW
Industry
Biotechnology

GI Innovation, Inc. engages in the development of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 88 full-time employees. The company went IPO on 2023-03-30. The firm is engaged in the business of generating revenue through license fees by technology transfer of new drug candidates in pre-clinical and early clinical stages. The core new drug pipeline includes products such as GI-101 immuno-oncology and GI-301 allergy treatment.

Intrinsic Value
59.67 KRW
Overvaluation 100%
Intrinsic Value
Price
G
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-15 377%
=
Net Income
₩-52B
/
Revenue
₩338.1m
What is GI Innovation Inc's current Net Margin?

The current Net Margin for GI Innovation Inc is -15 377%, which is above its 3-year median of -29 413.4%.

How has Net Margin changed over time?

Over the last 3 years, GI Innovation Inc’s Net Margin has decreased from -2 644.1% to -15 377%. During this period, it reached a low of -242 095.7% on Dec 31, 2024 and a high of -983.3% on Jun 30, 2024.

Back to Top